[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-382118-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-382118-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","blood-based-mrna-tests-as-emerging-diagnostic-tools-for-personalised-medicine-in-breast-cancer","Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer","","Molecular diagnostic tests support clinicians in decoding the biological basis of breast cancer and improving clinical management, including prediction, prognosis, and therapy selection. Tissue-based mRNA assays are established for recurrence-risk assessment, while blood-based mRNA assays are newly emerging. This review examines commercially available blood mRNA diagnostic tests for breast cancer, comparing their capabilities, and also surveys transcriptomic blood research toward future clinical assays and early detection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/blood-based-mrna-tests-as-emerging-diagnostic-tools-for-personalised-medicine-in-breast-cancer/382118/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/blood-based-mrna-tests-as-emerging-diagnostic-tools-for-personalised-medicine-in-breast-cancer/382118.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main clinical role of blood-based mRNA tests in breast cancer?","Question",{"text":63,"@type":64},"They are used to differentiate breast cancer from non-breast cancer subjects and to support diagnostic and management decisions, potentially offering information beyond conventional DNA testing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do blood-based mRNA assays compare with tissue-based mRNA tests?",{"text":68,"@type":64},"Tissue-based mRNA tests are already used routinely, whereas blood-based mRNA assays are newer. The review highlights advantages of blood tests such as minimal invasiveness and avoidance of tissue heterogeneity issues.",{"name":70,"@type":61,"acceptedAnswer":71},"What future directions does the review discuss for blood transcriptomic breast cancer research?",{"text":72,"@type":64},"Ongoing work targets blood transcriptome biomarkers that could help distinguish lymph node–positive versus lymph node–negative disease, separate breast cancer from benign breast conditions, and improve early detection timing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},382118,1791285405,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","cancers   \nReview  \nBlood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer  \nHelena ˇCelešnik 1,2 and Uroš Potoˇcnik 1,2,3, *  \nCitation: ˇCelešnik, H.; Potoˇcnik, U. Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer. Cancers 2023, 15, 1087 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers15041087  \nAcademic Editor: David Wong  \nReceived: 30 December 2022  \nRevised: 3 February 2023  \nAccepted: 6 February 2023  \nPublished: 8 February 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, 2000 Maribor, Slovenia  \n2 Center for Human Genetics & Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia  \n3 Department for Science and Research, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia  \n* [Correspondence: uros.potocnik@um.si](Correspondence: uros.potocnik@um.si); Tel.: +386-2-3305874  \nSimple Summary: Molecular diagnostic tests can facilitate molecular classification of breast cancer and its clinical management, including prediction, prognosis, and selection of therapy. Messenger RNA tests can supplement the clinically widely used DNA genetic testing. For instance, they can offer valuable information beyond DNA in cases where DNA variants are difficult to interpret. Moreover, several tissue-based mRNA tests for breast cancer are already used routinely in clinical practice to assess the recurrence risk and guide adjuvant endocrine therapy and chemotherapy. Here, we bring attention to the recently developed and commercially available blood mRNA diagnostic tests for breast cancer, which offer several advantages over tissue-based tests, including minimal invasiveness, absence of heterogeneity problems, cost-efficiency, and possibilities for early cancer detection well before the currently used conventional diagnostic approaches. We also investigate the state-of-the-art blood transcriptomic breast cancer research aimed at bringing novel blood transcriptome biomarkers and next-generation sequencing technology into clinical practice.  \nAbstract: Molecular diagnostic tests help clinicians understand the underlying biological mechanisms of their patients' breast cancer (BC) and facilitate clinical management. Several tissue-based mRNA tests are used routinely in clinical practice, particularly for assessing the BC recurrence risk, which can guide treatment decisions. However, blood-based mRNA assays have only recently started toemerge. This review explores the commercially available blood mRNA diagnostic assays for BC. These tests enable differentiation of BC from non-BC subjects (Syantra DX, BCtect), detection of small tumours \u003C10 mm (early BC detection) (Syantra DX), detection of different cancers (including BC) from a single blood sample (multi-cancer blood test Aristotle), detection of BC in premenopausal and postmenopausal women and those with high breast density (Syantra DX), and improvement of diagnostic outcomes of DNA testing (variant interpretation) (+RNAinsight) . The review also evaluates ongoing transcriptomic research on exciting possibilities for future assays, including blood transcriptome analyses aimed at differentiating lymph node positive and negative BC, distinguishing BC and benign breast disease, detecting ductal carcinoma in situ, and improving early detection further (expression changes can be detected in blood up to eight years before diagnosing BC using conventional approaches, while future metastatic and non-metastat","cbCaiijRSAauc2zV","https://ap.wps.com/l/cbCaiijRSAauc2zV","pdf",427809,23,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction\n## Breast cancer subtypes and clinical relevance\n## Molecular targets (ER, PR, HER2) and treatment implications\n## Challenges of triple-negative breast cancer","[{\"question\":\"What is the main clinical role of blood-based mRNA tests in breast cancer?\",\"answer\":\"They are used to differentiate breast cancer from non-breast cancer subjects and to support diagnostic and management decisions, potentially offering information beyond conventional DNA testing.\"},{\"question\":\"How do blood-based mRNA assays compare with tissue-based mRNA tests?\",\"answer\":\"Tissue-based mRNA tests are already used routinely, whereas blood-based mRNA assays are newer. The review highlights advantages of blood tests such as minimal invasiveness and avoidance of tissue heterogeneity issues.\"},{\"question\":\"What future directions does the review discuss for blood transcriptomic breast cancer research?\",\"answer\":\"Ongoing work targets blood transcriptome biomarkers that could help distinguish lymph node–positive versus lymph node–negative disease, separate breast cancer from benign breast conditions, and improve early detection timing.\"}]","Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer | PDF",1790249145,58]